Literature DB >> 580070

Combination versus successive single agent chemotherapy in lymphocytic lymphoma.

B J Kennedy, C D Bloomfield, D T Kiang, G Vosika, B A Peterson, A Theologides.   

Abstract

Fifty-three patients with advanced lymphocytic lymphoma were randomly assigned to treatment with the combination cyclophosphamide, vincristine, and prednisone (CVP) or the same agents used successively in maximal doses (C-V-P). Complete remissions occurred in 68% with CVP and 48% with C-V-P. For patients with nodular lymphoma, the complete remission rate was 81% with CVP and 46% with C-V-P. In patients with diffuse lymphoma a complete remission rate of 50% was obtained with both regimens. The median duration of response was longer for patients who obtained complete remission with CVP (37+ months) than for those entering remission with C-V-P (25+ months). More patients treated with CVP still survive. Current results suggest that CVP is a better induction regime than C-V-P in patients with nodular lymphoma. However, in patients with diffuse lympoocytic lymphoma, neither regimen results in more than 50% complete remissions or significant numbers of prolonged responses. More effective therapy is needed.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 580070     DOI: 10.1002/1097-0142(197801)41:1<23::aid-cncr2820410106>3.0.co;2-y

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

Review 1.  Economic burden of follicular non-Hodgkin's lymphoma.

Authors:  Talia Foster; Jeffrey D Miller; Mark E Boye; Mason W Russell
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

2.  Interferon alfa-2b and chlorambucil in the treatment of non-Hodgkin's lymphoma.

Authors:  T Chisesi; G Capnist; M Vespignani; G Cetto
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

3.  A phase II study of human rDNA alpha-2 interferon in patients with low grade non-Hodgkin's lymphoma.

Authors:  J Wagstaff; P Loynds; D Crowther
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study.

Authors:  Michinori Ogura; Yasuo Morishima; Yukio Kobayashi; Naokuni Uike; Susumu Sugai; Takaaki Chou; Masaharu Kasai; Ikuo Miura; Tohru Murayama; Yoshihiro Matsuno; Shigeo Nakamura; Shigeo Mori; Yasuo Ohashi; Kensei Tobinai
Journal:  Int J Hematol       Date:  2004-10       Impact factor: 2.490

Review 5.  The management of follicular lymphoma.

Authors:  A Z Rohatiner; T A Lister
Journal:  Drugs       Date:  1994       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.